Ascletis Pharma Inc.
1672
Kedudukan dalam Saham
#10460
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Harga Saham
$0.74836845
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$785.53M
Perubahan (1 hari)
1.12%
Perubahan (1 tahun)
-38.66%
Negara
CN
Perdagangan Ascletis Pharma Inc. (1672)
Kategori
Healthcare
EPS untuk Ascletis Pharma Inc. (1672)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham Ascletis Pharma Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk Ascletis Pharma Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
